Analyst Ratings for Enliven Therapeutics (ELVN)
ELVN Rating Summary
ELVN Price Target Summary
- Highest: $82.00 (Stifel)
- Lowest: $55.00 (Clear Street)
- Average: $72.89
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
=
Avg. $ Target:
$72.89 (+29.4%)
* Over Last 12-Mos
Rating Score: 10 / 10
Percentile Rank: 95%
Rating Score: 10 / 10
Percentile Rank: 95%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/18/2026 | William Blair | Andy Hsieh | New Coverage | Outperform (N/A) |
N/A (N/A) |
59.53 (56.33) |
-5.38% | Details |
| 8/18/2026 | Barclays | Etzer Darout | New Coverage | Overweight (N/A) |
78.00 (N/A) |
59.53 (56.33) |
-5.38% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
